2017 ASCO GU Public

Abstract #141, "Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial," presented by Joaquin Mateo, MD, The Institute of Cancer Research & The Royal Marsden

Orlando, FL - 2017 Genitourinary Cancers Symposium - Abstract #141, "Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial," presented by Joaquin Mateo, MD, The Institute of Cancer Research & The Royal Marsden, during Poster Session A at the 2017 Genitourinary Cancers Symposium in Orlando, Florida, here today, Thursday, February 16, 2017. The conference is the premier meeting on the science and treatment of Genitourinary Cancers from basic research to patient-based studies to larger clinical trials and population analyses in the United States. More than 3,000 experts from around the world are attending the meeting which is sponsored by the American Society of Clinical Oncology, the American Society of Radiation Oncology, and the Society of Urologic Oncology. Photo by © ASCO/Todd Buchanan 2017